Cabotegravir clinical trials

Studies by the year they started

62 studies that test it; most in 2020 (6)

Who runs them

Industry 42 · Other 20

ViiV Healthcare (39) · National Institute of Allergy and Infectious Diseases (NIAID) (8) · GlaxoSmithKline (2) · Beth Israel Deaconess Medical Center (1) · University of Witwatersrand, South Africa (1) · University of California, San Francisco (1) · Janssen Research & Development, LLC (1) · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia (1)

Often tested with

Tested in the same studies.

Rilpivirine (11) · Hyaluronidase (human recombinant) (2) · Tenofovir (2) · Emtricitabine (2) · Dolutegravir (2) · VH3810109 (1) · Lamivudine (1) · VRC07-523LS (1)

Studies

Open first, then newest update. How each study uses cabotegravir is read from its arms, and is right about nine times in ten.

Testing it · 62

• NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral SettingsNot yet recruitingPhase 4Duke UniversityNCT06854029Written as Cabotegravir Injection
• Cabotegravir-Hormone PK/PD Interactions for HIV PreventionRecruitingPhase 1Johns Hopkins UniversityNCT07672717Written as Cabotegravir Injectable Suspension (CAB LA)
• Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCTRecruitingPhase 3Africa Health Research InstituteNCT06250504Written as APRETUDE (cabotegravir) 600 mg\3 mL
• A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1RecruitingPhase 1/2ViiV HealthcareNCT07275606Written as Oral CAB
• Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject DrugsRecruitingPhase 4Massachusetts General HospitalNCT07199335Written as APRETUDE (cabotegravir)
• A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult ParticipantsRecruitingPhase 1ViiV HealthcareNCT05418868Written as Cabotegravir 200 mg/mL
• The Implementation of Pre-exposure Prophylaxis of Injectable CabotegravirRecruitingPhase 3Evandro Chagas National Institute of Infectious DiseaseNCT05515770Written as Cabotegravir Injection
• Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.Not yet recruitingPhase 3ANRS, Emerging Infectious DiseasesNCT06273943Written as Cabotegravir Tablets, for oral use.
• Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan AfricaNot yet recruitingPhase 3MRC/UVRI and LSHTM Uganda Research UnitNCT06133686Written as Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC), cabotegravir (CAB-LA)
• Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected AdultsActive, not recruitingPhase 3ViiV HealthcareNCT03299049Written as Cabotegravir Tablets
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)Active, not recruitingPhase 2ViiV HealthcareNCT06741397Written as CAB LA
• A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE TerritoriesCompletedPhase 4ViiV HealthcareNCT05514509Written as APRETUDE
• SEARCH CAB LA Dynamic Choice HIV Prevention Study ExtensionCompletedPhase 4University of California, San FranciscoNCT05549726Written as Cabotegravir Injectable Suspension
• The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifECompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT03635788Written as Oral CAB
• Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive ParticipantsActive, not recruitingPhase 3ViiV HealthcareNCT02938520Written as Cabotegravir (CAB) tablet
• Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)Active, not recruitingPhase 3ViiV HealthcareNCT06134362Written as CAB LA
• Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in BotswanaActive, not recruitingPhase 4Beth Israel Deaconess Medical CenterNCT05986084Written as Cabotegravir Injection [Apretude]
• A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)Active, not recruitingPhase 2ViiV HealthcareNCT05996471Written as Cabotegravir
• Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected AdultsActive, not recruitingPhase 3ViiV HealthcareNCT02951052Written as Cabotegravir (CAB) tablet
• Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult ParticipantsCompletedPhase 1ViiV HealthcareNCT04484337Written as Cabotegravir sodium (Oral Lead In)

See all 62 studies that test cabotegravir →

Codes

What other systems call cabotegravir · ClinicalTrials.gg INT006392

• MeSH (NLM) C584914cabotegravirConfirmed ClinicalTrials.gov, NLM
• UNII (FDA) HMH0132Z1QCABOTEGRAVIRConfirmed FDA, NLM, Wikidata
• RxNorm 2475077One source FDA
• Wikidata Q15411012cabotegravirConfirmed FDA, NLM, Wikidata
• NCI Thesaurus C169820CabotegravirOne source FDA
• DrugBank DB11751One source Wikidata

Also registered as cabotegravir sodium (UNII 3L12PT535M · RxNorm 2475076).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.